Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
About this trial
This is an interventional supportive care trial for Childhood Malignant Fibrous Histiocytoma of Bone focused on measuring childhood fibrosarcoma, childhood neurofibrosarcoma, childhood synovial sarcoma, chondrosarcoma, localized osteosarcoma, metastatic osteosarcoma, metastatic childhood soft tissue sarcoma, nonmetastatic childhood soft tissue sarcoma, metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor, localized Ewing sarcoma/peripheral primitive neuroectodermal tumor, previously treated childhood rhabdomyosarcoma, previously untreated childhood rhabdomyosarcoma, childhood alveolar soft-part sarcoma, childhood angiosarcoma, childhood epithelioid sarcoma, childhood leiomyosarcoma, childhood liposarcoma, localized childhood malignant fibrous histiocytoma of bone, metastatic childhood malignant fibrous histiocytoma of bone, childhood malignant mesenchymoma, dermatofibrosarcoma protuberans, childhood desmoplastic small round cell tumor
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosed with any of the following: Ewing's sarcoma Osteogenic sarcoma Rhabdomyosarcoma Other sarcomas (i.e., fibrosarcoma or synovial sarcoma) Scheduled to receive first course of chemotherapy that includes ≥ 75 mg/m² of anthracyclines Total modified Walsh score ≤ 2 (mucositis score) PATIENT CHARACTERISTICS: Must have a caregiver (parent, other relative, or friend) available to perform daily mucositis assessments Bilirubin ≤ 1.5 times upper limit of normal (ULN) ALT ≤ 5 times ULN Albumin ≥ 2 g/dL No history of hypersensitivity to any known component of AES-14 PRIOR CONCURRENT THERAPY: No prior glutamine (AES-14) No prior or concurrent head and/or neck radiation therapy No concurrent supplementation with another glutamine product No other concurrent agents for mucositis prophylaxis